Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Current therapeutic strategies for managing proteinuria after kidney transplantation are limited. Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist characterized by high selectivity, a nonsteroidal structure, and a lower risk of hormonal side effects, may play a protective role for kidney transplant recipients. Our study aimed to assess the safety and the efficacy of finerenone in reducing urinary protein and improving the graft function in kidney transplant recipients.
This study was a real world, single-center cohort study that consecutively enrolled kidney transplant recipients who were regularly taking finerenone between January 2024 and January 2025. Adult recipients who had a urinary albumin-to-creatinine ratio (UACR) ranging from 30 mg/g to≤5000 mg/g and a glomerular filtration rate of≥25 mL/min/1.73 m², with a less than 25% decrease in the function of the graft kidney over the last 3 months were included. Baseline data, laboratory parameters and adverse events were collected.
By February 2025, 61 kidney transplant recipients had been treated with finerenone. Based on exclusion criteria, 52 of these recipients were ultimately included in the study. The initial UACR for these recipients was 1210 mg/g. After one month of finerenone treatment, the median UACR dropped to 920 mg/g (p < 0.001). At the 12-months mark, the UACR remained significantly lower than the baseline level (p < 0.01). Regarding adverse events, 3 recipients stopped treatment due to hyperkalemia within two weeks. Serum creatinine and potassium levels stayed stable in the other kidney transplant recipients. Subgroup analyses of four treatment approaches, along with propensity score matching analysis, all showed consistent reductions in UACR with Finerenone therapy.
Finerenone can significantly reduce albuminuria in kidney transplant recipients and may protect against the progression of kidney disease.
